Applying AI to Drug Discovery and Development: Issues and Challenges
Pharma has invested heavily in Artificial Intelligence (AI) enabled technologies in the hope they would drive R&D efficiency gains. From identifying new targets and making screening more efficient to de-risking and accelerating clinical trials, AI tools are commonly applied across drug discovery and development. But is AI delivering value? Which AI tools are being applied successfully? What cultural challenges remain? In this report experts assess the value of AI to pharma’s R&D programmes and the challenges that must be overcome.
AbbVie, GlaxoSmithKline, Pfizer, Leo Pharma, Bristol Myers Squibb, Google, Amazon, Bayer, Insilico Medicine, Alphabet, Microsoft, McKinsey & Co, Netflix, Flatiron Health, Owkin, Recursion, Meta, DeepMind, Exscientia, Hugging Face, Morgan Stanley, PathAI, Proscia, Tempus, University of Washington
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook